IL13 and melanoma: In accordance with our in vitro data showing that IL-13-conjugated liposomes are preferentially taken up by M2 macrophages (Figure 1), IL-13-LCL-SIM monotherapy generated a strong reduction of intratumor macrophage marker F4/80 in the melanoma microenvironment (Figures 5 A,D, p < 0.001).